Your health care provider performs a thorough exam to rule out other nervous system conditions that have signs and symptoms similar to neuromyelitis optica.

In 2015, the International Panel for NMO Diagnosis proposed criteria to diagnose this illness.

To detect the condition, a health care provider generally reviews the medical history and symptoms and performs a physical exam. Other tests include:

  • Neurological exam. A neurologist examines the movements, muscle strength, coordination, sensation, memory, thinking, vision and speech. An eye doctor might be involved in the exam.
  • MRI. This imaging test uses a magnetic field and radio waves to create a detailed view of the brain, optic nerves and spinal cord. The health care provider might be able to detect lesions or damaged areas in the brain, optic nerves or spinal cord.
  • Blood tests. A health care provider might test the blood for the aquaporin-4-immunoglobulin G, also called AQP4-IgG antibody. This test shows a difference between NMO and MS. This test helps in making an early diagnosis of NMO.

    Other biomarkers such as serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain help detect relapses. A myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibody test also might be used to look for another inflammatory disorder that mimics NMO.

  • Lumbar puncture (spinal tap). During this test, the neurologist inserts a needle into the lower back to remove a small amount of spinal fluid. This test determines the levels of immune cells, proteins and antibodies in the fluid. This test might distinguish NMO from MS.

    The spinal fluid might show very high white blood cells during NMO episodes. This is greater than usually seen in MS, although this doesn't always happen.

  • Stimuli response test. To learn how well the brain responds to stimuli such as sounds, sights or touch, a test called evoked potentials test or evoked response test is done.

    Wires called electrodes are attached to the scalp and, in some cases, the earlobes, neck, arm, leg and back. Equipment attached to the electrodes records the brain's responses to stimuli. These tests help find lesions or damaged areas in the nerves, spinal cord, optic nerve, brain or brainstem.

  • Optical coherence tomography. This test evaluates the retinal nerve and its thickness. Patients with an inflamed optic nerve from NMO have more-extensive vision loss and retinal nerve thinning than people with MS.


NMO can't be cured, though long-term remission is sometimes possible with the right management. NMO treatment involves therapies to reverse recent symptoms and prevent future attacks.

  • Reversing recent symptoms. In the early stage of an NMO attack, a health care provider might give a corticosteroid medicine such as methylprednisolone (Solu-Medrol). It's given through a vein in the arm. The medicine is taken for about five days and then it's usually tapered off slowly over several days.

    Plasma exchange is often recommended as the first or second treatment, usually in addition to steroid therapy. In this procedure, some blood is removed from the body, and blood cells are mechanically separated from fluid called plasma. The blood cells are mixed with a replacement solution and the blood is returned to the body. This process can remove harmful substances and cleanse the blood.

    Health care providers also can help manage other possible symptoms, such as pain or muscle problems.

  • Preventing future attacks. Your health care provider might recommend that you take a lower dose of corticosteroids over time to prevent future NMO attacks and relapses.
  • Reducing relapses. Monoclonal antibodies have been shown in clinical trials to be effective in reducing the risk of NMO relapses. Eculizumab (Soliris, Elizaria), satralizumab (Enspryng) and inebilizumab (Uplizna) have been approved by the U.S. Food and Drug Administration (FDA) for relapses in adults.

    Rituximab (Rituxan) also has been shown in clinical trials to be effective in reducing NMO relapses. It's commonly used for NMO, although it's not currently FDA approved.

    Your health care provider also might recommend taking a medicine that suppresses the immune system. They might include azathioprine (Imuran, Azasan), mycophenolate (Cellcept), methotrexate (Trexall), cyclophosphamide (Cytoxan) or tocilizumab (Actemra.)

    Intravenous immunoglobulins, also known as antibodies, may decrease the relapse rate of NMO.

Clinical trials

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

Neuromyelitis optica care at Mayo Clinic

Nov. 23, 2022
  1. Wingerchuk DM, et al. Neuromyelitis optica spectrum disorder. New England Journal of Medicine. 2022; doi:10.1056/NEJMra1904655.
  2. Daroff RB, et al. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley's Neurology in Clinical Practice. 8th ed. Elsevier; 2016. https://www.clinicalkey.com. Accessed Aug. 25, 2022.
  3. Yanoff M, et al., eds. Inflammatory optic neuropathies and neuroretinitis. In: Ophthalmology. 5th ed. Elsevier; 2019. https://www.clinicalkey.com. Accessed Aug. 25, 2022.
  4. Glisson CC. Neuromyelitis optica spectrum disorders. https://www.uptodate.com/contents/search. Accessed Aug. 25, 2022.
  5. Symptoms and diagnosis of NMO. National Multiple Sclerosis Society. http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Neuromyelitis-Optica-(NMO)/Symptoms-and-Diagnosis. Accessed Aug. 25, 2022.
  6. Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; doi:10.1212/WNL.0000000000001729.
  7. Nimmagadda R. Allscripts EPSi. Mayo Clinic. July 6, 2022.
  8. Costello F. Neuromyelitis optica spectrum disorders. Continuum (Minneapolis, Minn.). 2022; doi:10.1212/CON.0000000000001168.
  9. Jarius S, et al. Neuromyelitis optica. Nature Reviews Disease Primers. 2020; doi:10.1038/s41572-020-0214-9.
  10. Held F, et al. Drug treatment of neuromyelitis optica spectrum disorders: Out with the old, in with the new? ImmunoTargets and Therapy. 2021; doi:10.2147/lTT.S287652.
  11. Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. The Lancet. 2004; doi:10.1016/S0140-6736(04)17551-X.
  12. Tahara M, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomized, double-blind, placebo-controlled trial. The Lancet Neurology. 2020; doi:10.1016/S14744422(20)30066-1.
  13. Pittock SJ, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. New England Journal of Medicine. 2019; doi:10.1056/NEJMoa1900866.
  14. Yamamura T, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. New England Journal of Medicine. 2019; doi:10.1056/NEJMoa1901747.
  15. Traboulsee A, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomized, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology. 2020; doi:10.1016/S14744422(20)30078-8.
  16. Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-Momentum): A double-blind, randomized placebo-controlled phase 2/3 trial. The Lancet. 2019; doi:10.1016/S0140-6736(19)31817-3.


Associated Procedures